IMMX vs IR · $640.7M cap vs P/E 49, rev $3.90B
Immix Biopharma Inc (IMMX) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Immix Biopharma Inc (IMMX) is a biotechnology company listed on US.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
IMMX does not have a complete income-statement cache yet.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
IMMX currently screens at market cap $640.7M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the IMMX and IR stock pages for the full models.
Not investment advice.